Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy

被引:13
|
作者
Plotnikov, Alexander
Niego, Be'eri
Ophir, Rachel
Korenstein, Rafi
Keisari, Yona [1 ]
机构
[1] Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel
来源
PROSTATE | 2006年 / 66卷 / 15期
关键词
electrostimulation; prostate cancer; immunostimulation; chemotherapy; low electric field;
D O I
10.1002/pros.20435
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. We developed a new anti-cancer treatment, which is a combination of chemotherapeutic agents and low electric field. In the present study we investigated its efficacy against prostate metastatic transgenic adenocarcinorna of mice (TRAMP). METHODS. Mice with 5, 10, and 13 mm in diameter intracutaneous tumors received Low Electric Field Cancer Treatment-Enhanced Chemotherapy (LEFCT-EC) with doxorubicin (10 mg/kg), and monitored for survival, and primary and metastatic tumors growth. RESULTS. The electric field increased the uptake of doxorubicin by TRAMP cells in vitro. In vivo use of LEFCT-EC reduced tumor size, prolonged survival, and cured 36-93% of the animals, dependent on treated tumor size. LEFCT-EC was more effective than surgery with or without chemotherapy. Part of the cured animals developed anti-tumor immunity and immunosuppression, significantly decreased the effectiveness of the treatment. CONCLUSION. Our results suggest that LEFCT-EC is an effective method for the destruction of metastatic prostate tumors.
引用
收藏
页码:1620 / 1630
页数:11
相关论文
共 50 条
  • [21] Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
    Beer, T. M.
    Armstrong, A. J.
    Rathkopf, D. E.
    Loriot, Y.
    Sternberg, C. N.
    Higano, C. S.
    Iversen, P.
    Bhattacharya, S.
    Carles, J.
    Chowdhury, S.
    Davis, I. D.
    de Bono, J. S.
    Evans, C. P.
    Fizazi, K.
    Joshua, A. M.
    Kim, C-S
    Kimura, G.
    Mainwaring, P.
    Mansbach, H.
    Miller, K.
    Noonberg, S. B.
    Perabo, F.
    Phung, D.
    Saad, F.
    Scher, H. I.
    Taplin, M-E
    Venner, P. M.
    Tombal, B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (05): : 424 - 433
  • [22] Early use of chemotherapy in metastatic prostate cancer
    Markowski, Mark C.
    Carducci, Michael A.
    CANCER TREATMENT REVIEWS, 2017, 55 : 218 - 224
  • [23] Chemotherapy in Prostate Cancer Beyond Metastatic CRPC
    Park, Jong Chul
    Eisenberger, Mario
    ONCOLOGY-NEW YORK, 2015, 29 (12): : 964 - 965
  • [24] Metronomic Oral Cyclophosphamide Prednisolone Chemotherapy Is an Effective Treatment for Metastatic Hormone-refractory Prostate Cancer after Docetaxel Failure
    Ladoire, Sylvain
    Eymard, Jean Christophe
    Zanetta, Sylvie
    Mignot, Gregoire
    Martin, Etienne
    Kermarrec, Isabelle
    Mourey, Eric
    Michel, Frederic
    Cormier, Luc
    Ghiringhelli, Fracois
    ANTICANCER RESEARCH, 2010, 30 (10) : 4317 - 4323
  • [25] Involvement of the immune response in the cure of metastatic murine CT-26 colon carcinoma by low electric field-enhanced chemotherapy
    Plotnikov, A
    Tichler, T
    Korenstein, R
    Keisari, Y
    INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (05) : 816 - 824
  • [26] Enhanced blebbing as a marker for metastatic prostate cancer
    Khan, Zeina S.
    Santos, Julianne M.
    Vaz, Neil G.
    Hussain, Fazle
    BIOMICROFLUIDICS, 2019, 13 (03)
  • [27] Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling
    Myers, Charles E.
    Basu, Gargi
    Wright, Brian
    Mahanes, Joanne
    Spinelli, Anthony
    CASE REPORTS IN ONCOLOGY, 2012, 5 (01): : 154 - 158
  • [28] Current place of chemotherapy in the treatment of hormone-refractory metastatic prostate cancer.
    Breton, X
    Lechevallier, E
    Coulange, C
    PROGRES EN UROLOGIE, 2005, 15 (03): : 398 - 404
  • [29] Metastatic hormonorefractory prostate cancer: treatment of disease progression after taxanes based chemotherapy
    Verze, P.
    Longo, N.
    Creta, M.
    Di Lorenzo, G.
    Imbimbo, C.
    Arcaniolo, D.
    Vivaldi, O.
    Riccio, R.
    Mirone, V.
    UROLOGIA JOURNAL, 2009, 76 : S59 - S63
  • [30] Chemotherapy for metastatic castrate-sensitive prostate cancer
    R E Miller
    C J Sweeney
    Prostate Cancer and Prostatic Diseases, 2016, 19 : 139 - 144